论文信息 - A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) - 字舞流文

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Friedberg | J. Liesveld | B. Hill | C. Zent | P. Barr | A. Baran | D. Mulford | P. Sportelli | P. Meacham | H. Miskin | Ashley Morrison | M. Weiss | Andrew Bui | Shuo Ma | Kelsey Holkovic